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Background:  From  2007  to 2009,  the  Netherlands  experienced  a  major  Q fever  epidemic.  Long-term  sero-
logical  follow-up  of  acute  Q  fever  patients  enabled  the  investigation  of  longitudinal  antibody  responses
and  estimating  the  onset  of the seroresponse  in  individual  patients.
Methods:  All  available  IgG  and  IgM  phase  I and  II antibody  measurements  determined  by  immunoﬂuo-
rescence  assay  at month  3, 6, 12, and 48  from  2321  acute  Q fever  patients  were  retrospectively  analyzed.
Characteristic  features  of  the antibody  response  were  calculated.  To  model  the  seroresponse  onset,  sero-
logical  data  from  patients  diagnosed  with  a positive  C.  burnetii  PCR  test  (n =  364), and  therefore  with  a
known  time  of infection,  were  used  as reference.
Results: In  9083  IgG  samples  and  3260  IgM samples  large  heterogeneity  in  shape  and  magnitude  of
antibody  responses  was  observed.  Phase  II reached  higher  levels  than  phase  I, and  IgG  antibodies  wereinetics more  persistent  than  IgM.  The  estimated  seroresponse  latency  allowed  for determining  the  time  since
start  of  the  seroresponse  from  the  concentrations  of  the  different  antibodies  against  C.  burnetii.
Conclusions:  The  extraordinary  large  serological  dataset  provides  new  insight  into  the kinetics  of  the
immunoglobulins  against  C.  burnetii  antigens.  This  knowledge  is  useful  for seroprevalence  studies  and
helps  to  better  understand  infection  dynamics.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
From 2007 to 2009, the Netherlands experienced a major Q fever
pidemic with >3500 notiﬁed cases, most of whom resided in the
outhern part of the country (van der Hoek et al., 2010). The major-
ty of cases was diagnosed in one regional hospital, the Jeroen Bosch
ospital (JBH) in ’s-Hertogenbosch.
The reference test for the serological diagnosis of Q fever is
mmunoﬂuorescence assay (IFA) (Maurin and Raoult, 1999). One
mportant disadvantage of using serology for patient diagnosis is
he lag in antibody development of seven to ﬁfteen days after
he onset of symptoms (Maurin and Raoult, 1999; Anderson et al.,
013). During this interval from symptom onset until a mounted
∗ Corresponding author at: Jeroen Bosch Hospital, Department of Medical Micro-
iology and Infection Control, P.O. Box 90153, 5200 ME  ’s-Hertogenbosch, The
etherlands. Tel.: +31 073 553 2875; fax: +31 073 553 2136.
E-mail address: p.schneeberger@jbz.nl (P.M. Schneeberger).
ttp://dx.doi.org/10.1016/j.epidem.2015.07.001
755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article
.0/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
antibody response, however, DNA from Coxiella burnetii can be
detected in serum or plasma by polymerase chain reaction (PCR)
(Schneeberger et al., 2010; Wielders et al., 2013). C. burnetii DNA
becomes undetectable by the time IgG antibodies can be measured
(Schneeberger et al., 2010). Another disadvantage of serology for
diagnosis of acute cases in post-epidemic and endemic situations
is the persistence of IgM phase II antibodies (Wegdam-Blans et al.,
2012).
A previous study investigated the time course of antibody
responses against C. burnetii in a cohort of 344 acute Q fever patients
using a dynamic mathematical model, and showed that antibodies
against C. burnetii are highly persistent (Teunis et al., 2012a). For
early detection of chronic Q fever, a condition with high morbidity
and mortality, the JBH offered standard serological follow-up to all
acute Q fever patients after three, six, and twelve months. In addi-
tion, serological data were collected approximately four years after
diagnosis, in the context of a research project.
Serological follow-up is available for >2300 cases with >1300 at
approximately four years after diagnosis. This exceptional database
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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fig. 1. Theoretical characteristics of the antibody response: time to onset, onset to
eak, time to peak, peak titre, and half time (not on scale).
akes it possible to greatly increase our understanding of the
ntibody responses to C. burnetii infection which display consider-
ble natural variation between different individuals (Teunis et al.,
012a; Tissot-Dupont et al., 1994; Limonard et al., 2010; van der
oek et al., 2011).
More insight into longitudinal antibody responses, including
ime to onset of the seroresponse, time to peak titre, and decay rates
s important for several reasons, namely: (i) to determine adequate
erologic diagnostic criteria for acute, past-resolved, and chronic Q
ever, (ii) to deﬁne notiﬁcation criteria (acute Q fever is a notiﬁable
isease in many countries), (iii) to evaluate seroprevalence studies
nd help interpreting the outcomes of these studies, and (iv) to be
ble to diagnose chronic Q fever reliably.
The aim of this study was: (i) to investigate longitudinal anti-
ody responses and describe characteristic features in terms of:
ime from symptom onset to onset seroresponse, time from onset
eroresponse to peak titre, magnitude of peak titre, and half time
f antibody decay (Fig. 1), (ii) to estimate the onset of the serore-
ponse from antibody concentrations and investigate the relation
etween modelled and observed date of symptom onset, and (iii)
o estimate the onset of a Q fever outbreak or epidemic based on
erologic information.
. Methods
.1. Data collection
Patients suspected of an acute Q fever infection were referred
y a general practitioner (GP) or hospital physician for laboratory
onﬁrmation. All patients diagnosed with acute Q fever from 2007
o 2009 at the Laboratory for Medical Microbiology of the JBH were
ffered standard three-, six-, and twelve-month serological follow-
p. A laboratory-conﬁrmed acute Q fever case in our laboratory is
eﬁned as: (i) both IgM and IgG phase II antibody titres ≥1:32 by
FA (Focus Diagnostics, Inc., Cypress, CA, USA), or (ii) IgM phase II
ntibody titres ≥1:32 by IFA in the diagnostic sample and IgG phase
I ≥1:32 in follow-up, or (iii) enzyme-linked immunosorbent assay
ELISA; Virion\Serion, Würzburg, Germany) IgM phase II positive
nd IFA IgG phase II ≥1:32, or (iv) a positive PCR (in-house assay)
Schneeberger et al., 2010; Wielders et al., 2013) result preceding
eroconversion in IFA.
At diagnosis, the IFA IgM test was sometimes replaced by ELISA
gM phase II according to the diagnostic algorithm used (Jager et al.,
011). At three-, six-, and twelve-month follow-up, mainly IgG
hase I and phase II IFA tests were performed. Therefore, the num-
er of samples available for IgM phase I and phase II analyses were
ower than for IgG.
In addition to the standard serological follow-up, a four-year
ollow-up study was conducted for patients with an obtained bloodmics 13 (2015) 37–43
sample twelve months after diagnosis and aged 18 years or older.
IFA was again used to determine IgG and IgM phase I and II anti-
bodies in serum. The Medical Ethical Committee Brabant (number
NL35654.028.11) and the Internal Review Board of JBH approved
this study, and informed consent was obtained from participants.
2.2. Exclusion
Patients were excluded for analysis when only a PCR and ELISA
IgM phase II were performed at diagnosis with no follow-up sample
(thus no IFA results available), or when a proven chronic Q fever
infection (IgG phase I ≥1:1024 and a positive PCR) or a probable
chronic infection was  present at diagnosis.
2.3. Parameter estimation and analysis
Kinetics of serum antibody responses have been modelled using
a within host model describing the interaction between pathogens
and host defences in a highly simpliﬁed manner. Brieﬂy, dur-
ing infection, pathogens multiply with their own  intrinsic rate,
and they are inactivated (removed) with a rate proportional
to the serum antibody concentration. During that same period,
serum antibody concentrations increase exponentially. As soon as
pathogens are removed, antibody concentrations stop increasing
but instead start to decay. Therefore, there are two episodes of the
seroresponse:
1. during infection (colonization): y(t) = y0e1t ; pathogen numbers
reach zero at time t past inoculation, when antibody concentra-
tions peak at y(t1) = y0e1t1 ;
2. after infection antibody concentration decay as y(t) =(
y1−r1 −(1−r)ı(t−t1)
)1/(1−r)
y(t)=
(
y1−r1 −(1 − r)ı(t − t1)
)1/(1−r)
,
where y0 is the baseline antibody concentration (before infec-
tion), 1 is the peak antibody concentration, y1 is the growth
rate of the immune level during the infection period, r is a
shape factor that describes the extent to which the decay
in antibody concentration differs from an exponential decay
(limiting case r → 1 approaches exponential decay; log(antibody
titre) decreases linear in time), and ı is a decay rate parameter
deﬁning the time scale of antibody decay. Details of the model
are published separately (de Graaf et al., 2014). Measurement
errors were assumed lognormal (Teunis et al., 2012a,b): the
contribution of any observed (log) antibody concentration to
the likelihood is (log(Y)|log(y(t)), y) where  is the probability
density of the normal distribution with standard deviation y.
Antibody concentrations measured by IFA are all interval cen-
sored, that is, observations are determined within intervals, usually
of twofold change in concentration. For a quantitative interpreta-
tion of the observed antibody titres, the titres must be translated
to antibody concentrations. Low (and sometimes high) concen-
trations may  also have an open-ended interval (such as <1:32, or
>1:4096) (Teunis et al., 2012a). To treat such data appropriately, the
likelihood can be written as ˚(log(Y1)|(y(t)), y) − ˚(log(Y1)|(y(t)),
y) where  ˚ represents the cumulative normal distribution and
the pair (Y1, Y0) are the upper and lower margin of the observed
interval, respectively. Care has been taken to allow these margins
to include zero and inﬁnity, to account for open-ended intervals.
The above model can be conveniently implemented into a
Bayesian framework, to account for variation in response param-
eters among individual subjects (Teunis et al., 2012a,b). For the
present paper, we  have implemented the model into JAGS/rjags
(Just Another Gibbs Sampler; a programme for the analysis of
Bayesian hierarchical models using Markov Chain Monte Carlo
(MCMC) simulation), and made separate (independent) runs for
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ach of the four antibodies (IgG phase I and II and IgM phase I and II).
ate parameters were all log transformed and vague normal priors
ere chosen as reported separately (de Graaf et al., 2014). Pre-
icted serum antibody concentrations were obtained by sampling
rom population priors of all parameters, and calculating Monte
arlo samples (1000 burn-in samples, then 10,000 samples with
hinning 10 resulting in 1000 posterior samples). Median time to
nset (from symptom onset to onset seroresponse), onset to peak
from onset seroresponse to peak titre), peak titre, and half time
time to decrease from peak titre to half of the peak titre) and
heir 95% credible intervals (95% CIs) were estimated for the four
ntibodies by MCMC  (Fig. 1). These characteristics illustrate the
ariability of the individual antibody responses. It is important to
ote that these characteristics are theoretical features of the serore-
ponse, one could not measure these characteristics in patients in
eal-life.
A separate set of models was constructed with response param-
ters dependent on age and gender of the patients, to study
he variation of the characteristic features of the serum antibody
esponse with age and gender.
Onset of the seroresponse could be estimated by expressing
nset relative to the date of the ﬁrst sample (which is always avail-
ble), and treat that (relative) onset as an additional variable to be
stimated. Assuming that patients diagnosed with a positive PCR
esult provided the most reliable subset of patients to determine
nset of seroresponse, as PCR is only positive in the ﬁrst two  weeks
fter onset of symptoms (Schneeberger et al., 2010), we included
heir seroresponse onsets as known, and set those onsets for all
ther patients to “missing”, to let the model estimate the date of
nset of the seroresponse in all those patients without positive PCR
ig. 2. Observed individual and model ﬁtted longitudinal antibody against C. burnetii me
ponse: IgG phase I (a), IgG phase II (b), IgM phase I (c), and IgM phase II (d). The grey 
cute  Q fever patient; symbols indicate censoring: circles at the geometric mean when b
ither  a lower level (downward triangle) or an upper level (upward triangle). The black l
orresponding 95% credible interval (upper and lower line). Note that for IgM phase I the
s  not visible.ics 13 (2015) 37–43 39
outcome by using the IgG and IgM phase I and phase II antibody lev-
els. A suitably vague prior was chosen to allow for a sufﬁciently
broad interval of the estimated periods. All data were analyzed
using R version 3.0.1 (The R Foundation for Statistical Computing,
Vienna, Austria) (R Core Team, 2013) and JAGS/rjags.
3. Results
In the JBH, 2347 Q fever patients were diagnosed between 2007
and 2009. We  excluded 26 patients; for 15 patients no IFA results
were available and 11 patients had a proven or probable chronic
infection at time of Q fever diagnosis.
The remaining 2321 acute Q fever patients provided 9083 sam-
ples for IgG phase I and II antibody determination. The median age
at diagnosis was 49 years (range 2–96; interquartile range (IQR)
38–59), 59.0% was male (n = 1370), and the median follow-up time
was 371 days (IQR 358–1372). IgM phase I and II were analyzed in
3260 samples from 2124 patients.
Fig. 2 shows the observed individual longitudinal antibody lev-
els (IgG and IgM phase I and II) against C. burnetii measured by
IFA, together with the model ﬁtted antibody concentrations start-
ing at the onset of the seroresponse. IgM phase I showed the fastest
decline of the four antibodies measured, while IgG phase II reached
the highest levels. In addition, large heterogeneity in antibody
responses was  observed between individuals (grey lines, each line
represents one patient). We  did not ﬁnd any clear differences in
antibody patterns for men  and women, or for different age cate-
gories. The geometric mean antibody concentrations over time for
the four antibodies are shown in Fig. 3.
asured by immunoﬂuorescence assay starting at the estimated onset of the serore-
lines are the observed individual antibody concentrations; one line indicates one
oth upper and lower levels have been observed, triangles indicate the absence of
ines show the median of the ﬁtted antibody concentrations (middle line) with the
 large variability in observed titres inﬂates the credible intervals: the lower margin
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Table 1
Estimated median and 95% credible interval of the time to onset (time from symptom onset to onset of seroresponse), time to peak (time from symptom onset to peak titre),
magnitude of peak titre, and half time of antibody decay (time to decrease from peak titre to half of the peak) for IgG and IgM phase I and phase II antibodies against Coxiella
burnetii.
Antibody Time to onset (days) Time to peak (days) Peak titre (IFA units) Half time (days)
Median (95% CI) Median (95% CI) Median (95% CI) Median (95% CI)
IgG phase Ia 29 (0–185) 42 (0–198) 141 (6–3.5  × 104) 650 (17–8.7  × 104)
IgG  phase IIa 5 (0–182) 18 (0–196) 2120 (69–1.2  × 106) 937 (44–7.1 × 103)
IgM  phase Ib 17 (0–209) 76 (17–253) 245 (2–2.9  × 105) 122 (12–1.6 × 103)
IgM  phase IIb 14 (0–205) 47 (8–237) 580 (28–4.3  × 104) 400 (25–6.4  × 103)
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TFA: immunoﬂuorescence assay; 95% CI: 95% credible interval.
a Number of subjects: 2321; number of observations: 9083.
b Number of subjects: 2124; number of observations: 3260.
The time to onset seroresponse is extremely variable, as indi-
ated by the large 95% CIs, ranging from zero to six months with a
edian less than one month (Table 1). Phase II antibodies reached
igher levels than phase I, and IgG antibodies had longer half times
han IgM, indicating longer persistence of the IgG antibodies. The
raphs of the onset to peak for IgG phase I and II show a narrow
istribution, indicating that there was limited variation in the dis-
ribution with relatively small statistical uncertainty (Fig. 4). The
istribution is less narrow for IgM antibodies (Supplemental Fig.
).
We assessed whether there were differences between men  and
omen of different ages but no obvious patterns were observed,
xcept for the time to peak for IgG phase I and II: the time from
nset seroresponse to peak titre increased in men  with increasing
ge, while there was no such pattern observed for women. We also
nvestigated the time from onset seroresponse to peak, peak titre,
nd half time of antibody decay for patients diagnosed by posi-
ive PCR results (n = 364) versus patients with negative PCR results
n = 213), and for hospitalized (n = 324) versus non-hospitalized
atients (n = 1997), but no clear patterns were found.
Fig. 5 shows the difference between the date of ﬁrst symptoms
vailable in our dataset and the estimated onset of the seroresponse
alculated by the model (time to onset in Fig. 1). The delay from
ime to onset seroresponse seems to be the smallest in 2009 (best
verlay with the estimated date of symptom onset); while in 2007
here is a larger delay between the recorded date of symptom onset
nd the estimated date of onset seroresponse. Moreover, the esti-
ated seroresponse seems to have a wider distribution than the
istogram, which reﬂects the heterogeneity of antibody responses.
ig. 3. Geometric mean of antibody levels to Coxiella burnetii infection (IgG and IgM
hase I and phase II antibodies) measured by immunoﬂuorescence assay over time
tarting at the estimated onset of the seroresponse. The large heterogeneity that is
bserved among individuals is not shown in this Figure but can be seen in Fig. 2 and
able 1.4. Discussion
Since the Dutch Q fever epidemic was  the largest Q fever epi-
demic ever reported so far, and serological follow-up was available
for the vast majority of the patients involved (Morroy et al., 2013),
the dataset used in this study is extraordinary large and complete.
The results of the seroresponse model suggest that IgG phase
II appears earlier than IgM phase II. The generally accepted order
of detecting antibodies by laboratory diagnostic tests is the other
way around, but it has also been reported that these two antibody
types appear almost simultaneously (Maurin and Raoult, 1999;
Anderson et al., 2013; Tissot-Dupont et al., 1994; Peacock et al.,
1983; Dupuis et al., 1985; Guigno et al., 1992; Wegdam-Blans et al.,
2010). However, large heterogeneity was  observed in time to onset
seroresponse, as shown by the large 95% CIs, indicating that the
median times to onset for the two  immunoglobulin isotypes do
not seem to be different. It should be noted that the onset of the
seroresponse is a theoretical feature that cannot be measured in
real-life, and it is not identical to the ﬁrst appearance of antibodies
by a diagnostic test. Therefore, this model adds new information to
the antibody measurements available from actual patients. From
previous studies, it is known that there is a large variability in
the magnitude of the peak titre and the antibody decay (Teunis
et al., 2012a; Dupuis et al., 1985; Guigno et al., 1992; Worswick
and Marmion, 1985), but the present study showed that there also is
large variation between individuals at the beginning of the antibody
response.
There are two explanations for the large uncertainty: the huge
variation in antibody responses between individuals, and the
absence of a sample early after the infection in many of the cases.
During the increase of the antibody response, antibody concentra-
tions change fast within a relatively short time period, while the
decay takes a long time with slowly decreasing concentrations.
When there is no sample available, or data are only recorded as
“positive” or “negative”, there is little information on the shape of
the rising part of the antibody response (Fig. 1), and consequently
the estimation of the seroresponse onset remains uncertain. As this
is a Bayesian hierarchical model, in case of missing data any esti-
mates are based on the group level estimates, but with increased
uncertainty.
We conﬁrmed that IgG phase II reaches the highest peak titre of
the four different antibodies (Tissot-Dupont et al., 1994; Peacock
et al., 1983; Dupuis et al., 1985), that phase II reaches higher levels
than the corresponding phase I (Wegdam-Blans et al., 2012; Teunis
et al., 2012a; Tissot-Dupont et al., 1994; van der Hoek et al., 2011;
Peacock et al., 1983; Dupuis et al., 1985), and that IgG antibodies
were more persistent than IgM (longer half time) (Teunis et al.,
2012a; Dupuis et al., 1985; Guigno et al., 1992). The longest half
time was  found for IgG phase II, which makes this the preferred
antibody for the detection of a past C. burnetii infection and in sero-
prevalence studies (Hogema et al., 2012; Schimmer et al., 2012).
Even though IgG was  more persistent than IgM, the long persistence
C.C.H. Wielders et al. / Epidemics 13 (2015) 37–43 41
Fig. 4. Three theoretical characteristics of the IgG phase I (left) and phase II (right) antibody titres against Coxiella burnetii: onset to peak (onset of seroresponse to peak titre)
(a:  IgG phase I; b: IgG phase II), magnitude of peak titre (c: IgG phase I; d: IgG phase II), and half time of antibody decay (time to decrease from peak titre to half of the peak
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012b), and note that the axes of the graphs differ. Characteristics are theoretical b
f IgM antibodies is remarkable, since it is considered a marker
or acute infection. Especially in late epidemic, post-epidemic, and
ndemic areas, the persistence of antibodies makes the interpre-
ation of diagnostic results sometimes difﬁcult, and the acute Q
ever diagnosis can therefore not be based on a single serum sam-
le in these areas (Wegdam-Blans et al., 2012). A single isolated
gM phase II positive test result in combination with fever, pneu-
onia, or hepatitis, however, is classiﬁed as acute Q fever in the
armonised European Union Q fever case deﬁnition (EFSA Panel on
nimal Health and Welfare (AHAW), 2010).No obvious differences in the longitudinal responses have been
ound between men  and women or different age categories, as pre-
iously reported (Teunis et al., 2012a). However, one exception was
bserved: the time from onset seroresponse to peak titre appears like a probability distribution (the area under the curve is always 1) (Teunis et al.,
 one could not measure these characteristics in patients in real-life.
to increase in men  of increasing age, while women do not show this
effect. No literature exists, to our knowledge, on the differences in
antibody responses to C. burnetii between men  and women.
Furthermore, the times to peak in the present study seem dif-
ferent from the ones that have been described by Tissot-Dupont
et al. among 58 acute Q fever cases where IgM phase I and phase II
reached peak values at week four, IgG phase II at week six, and IgG
phase I at week 24 (Tissot-Dupont et al., 1994). Nonetheless, these
are all within the 95% CIs of the present study. However, Tissot-
Dupont et al. used a different IFA test, and it was not described at
which time intervals data were collected and how many samples
were available at each time point. Because there is a large vari-
ation in individual antibody responses, this might partly explain
the differences between both studies. Because of the large sample
42 C.C.H. Wielders et al. / Epide
Fig. 5. Estimated timing of the seroresponse onset in acute Q fever patients com-
pared with reported date of symptom onset (the epidemic curve). The histogram
represents the date of symptom onset for acute Q fever patients with a known date
of ﬁrst symptoms (n = 2062). The black line represents the smoothed density of the
estimated date of the seroresponse onset for acute Q fever patients not diagnosed
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2y a positive PCR (n = 1974) by combining estimates for all four serum antibodies,
nd the grey lines indicate the 95% credible interval of the estimated date of the
eroresponse onset.
ize, our study is expected to provide more reliable estimates of the
ariability in seroresponse patterns than any previous study.
Our method to estimate the date of seroresponse onset from
he four different immunoglobulin concentrations shows that it
s possible to estimate this date for acute Q fever patients who
ere diagnosed at an arbitrary time during their antibody response.
his method enables the estimation of the latency of the serore-
ponse and presumed date of symptom onset in any individual with
ntibodies against C. burnetii antigens. This could be a useful tool
n seroprevalence studies, and in understanding dynamics of the
nfection (Teunis et al., 2012b) and the variation in seroresponses
mong acute patients. Furthermore, it can be helpful in the diag-
osis of Q fever, either acute or past-resolved, which is difﬁcult to
istinguish with regular Q fever laboratory assays in late epidemic,
ost-epidemic, and endemic areas. This method makes it possible
o get an indication of whether the infection occurred recently or a
hile ago.
A time lag was observed between the recorded symptom onset
histogram) and the estimated onset of the seroresponse (black
ine), showing the largest delay in 2007 and the smallest in 2009.
hese differences between the three epidemic years can be partly
xplained by the increasing numbers of cases and the decreasing
iagnostic delay during the years (Dijkstra et al., 2012). For the large
elay in 2007, an additional explanation is the retrospective active
ase ﬁnding among hospitalized pneumonia patients in the high-
ncidence area (Dijkstra et al., 2012). The date of symptom onset
or these patients might be inﬂuenced by recall bias, as the public
ealth service could only ask for the date of symptom onset when
he hospitalization had been linked to a positive Q fever serology
est. We  observed that the ﬁrst or the ﬁfteenth days of a month are
tatistically signiﬁcantly more likely to be recorded than other days
f a month, which inﬂuences the histogram and contributes to the
bserved discrepancy.
Interestingly, a small additional peak in estimated onset of
eroresponses appeared at the end of 2009 (Fig. 5). This peak rep-
esents acute Q fever patients who have a delayed seroresponse
ith respect to the recorded symptom onset. No differences in
ollow-up rates were observed between patients diagnosed late
009 and patients diagnosed earlier. We  hypothesize that thismics 13 (2015) 37–43
peak may  be caused by a combination of two  factors. First, the
2009 pandemic inﬂuenza A(H1N1) resulted in increased diagnos-
tic testing for pathogens causing respiratory symptoms in 2009
(Jager et al., 2011). Around the same time as the peak observed in
Fig. 5, the number of 2009 pandemic inﬂuenza A(H1N1) cases in the
Netherlands also increased (van ’t Klooster et al., 2010). Since we
observed a large variation in individual antibody responses against
C. burnetii antigens, the increased diagnostic testing might have
caused more acute Q fever patients detected with delayed antibody
responses as would have been expected without the 2009 pan-
demic inﬂuenza A(H1N1). Another hypothesis is that the infection
dose inﬂuences the incubation period of the C. burnetii infection,
a lower dose leading to a longer incubation period (Tigertt et al.,
1961). As the Q fever epidemic showed seasonal trends with the
highest incidence in spring and early summer due to the lambing
season (van der Hoek et al., 2010; Schimmer et al., 2011) and C.
burnetii is able to survive for a prolonged time in the environment
(van der Hoek et al., 2012), the dose of C. burnetii that is inhaled
by humans is expected to be lower in autumn than in spring. This
lower dose could cause a prolonged incubation period in some indi-
viduals, which might have become notable due to the large number
of patients that have been tested. It is also the ﬁnal year of the epi-
demic and environmental concentrations of C. burnetii may  have
been waning.
This study is more advanced than a previously published study
(Teunis et al., 2012a) in several respects. First, the number of
included patients is much higher and the duration of follow-up is
longer. Secondly, the model used in the current study is an improve-
ment of the previously used model. The increase and decrease in
antibody levels during the seroresponse are described by different
mechanisms, providing additional ﬂexibility compared to the basic
predator–prey model used previously (Teunis et al., 2012a). Note
however, that despite the large number of patients and samples,
the 95% CIs of the characteristic features of the antibody response
showed large ranges, as described above, and the distributions
were highly skewed. In both studies, longitudinal data analysis
was based on the same measurement error model: IFA data are
semi-quantitative and sometimes results were only recorded as
“positive” or “negative”. Consequently, all data are treated as inter-
val censored, in some cases with one of the margins missing (i.e.,
zero or inﬁnity).
One of the limitations of this study is the study population repre-
sentativeness. Our study population consists of patients diagnosed
with acute Q fever in the main epidemic area of the Dutch Q fever
epidemic. Laboratory tests for Q fever were requested by the gen-
eral practitioner or hospital physician because of a suspicion of
acute Q fever infection. However, not all persons with C. burnetii
infection will visit their GP, because approximately 40% of persons
infected with C. burnetii do not develop symptoms (Maurin and
Raoult, 1999). Of the 60% symptomatically infected, not all will seek
medical care. Therefore, the study population is not representative
for all patients with a C. burnetii infection, but is expected to be
representative for those with a clinically relevant Q fever infection.
Furthermore, especially in 2009 during the peak of the epidemic
and two  years after the ﬁrst cases were diagnosed, most people
and GPs in the catchment area of the Laboratory for Medical Micro-
biology of the JBH were aware of the ongoing epidemic and the
clinical presentation of acute Q fever. Other limitations are the pre-
cision of the antibody measurements (in particular the censoring
of observations), absence of early samples, the limited number of
patients with positive PCR results (as possible proxy of infection),
and to be unable to distinguish antibody responses in symptomatic
and asymptomatic patients.
In conclusion, this study gives detailed insight into the time
to onset seroresponse, onset seroresponse to peak, magnitude of
peak titre, and half time of antibody decay against C. burnetii
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